Treatment of Obesity Using Non-Daily Administration of 6-O-(4-Dimethylaminoethoxy) Cinnamoyl Fumagillol
US-2016243073-A1 · Aug 25, 2016 · US
Methods of treating an overweight subject
US9649293B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9649293-B2 |
| Application number | US-201414573495-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 17, 2014 |
| Priority date | Apr 7, 2010 |
| Publication date | May 16, 2017 |
| Grant date | May 16, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a MetAP2 inhibitor.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting further weight gain in a patient in need thereof, wherein the patient is overweight and is not obese, comprising administering a pharmaceutically effective amount of a MetAP2 inhibitor selected from the group consisting of fumagillin, fumagillol, O-(4-dimethylaminoethoxycinnamoyl) fumagillol and pharmaceutically acceptable salts thereof to the patient; and wherein upon discontinuation of administration of said MetAP2 inhibitor, weight gain is further inhibited in the patient at least for about 1 month. 2. The method of claim 1 , wherein said MetAP2 inhibitor is administered subcutaneously or intravenously. 3. The method of claim 1 , wherein said MetAP2 inhibitor is selected from the group consisting of fumagillin, fumagillol and pharmaceutically acceptable salts thereof. 4. The method of claim 1 , wherein said MetAP2 inhibitor is selected from O-(4-dimethylaminoethoxycinnamoyl) fumagillol and pharmaceutically acceptable salts thereof. 5. The method of claim 1 , wherein administering results in decreased body fat and a substantial maintenance of muscle mass in said patient. 6. The method of claim 1 , wherein upon administration, fat oxidation is enhanced as compared to a patient on a restricted food intake diet alone. 7. The method of claim 1 , further comprising co-administering an additional weight loss agent. 8. The method of claim 1 , further comprising administering a food restricted diet to said patient. 9. The method of claim 1 , wherein said administration occurs at least daily. 10. The method of claim 1 , wherein said administration occurs at least weekly.
Assignees
Inventors
Classifications
the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46) · CPC title
not condensed and containing further heterocyclic rings, e.g. cromakalim · CPC title
against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title
interfering nucleic acids [NA] · CPC title
Antisense · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9649293B2 cover?
- The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a MetAP2 inhibitor.
- Who is the assignee on this patent?
- Zafgen Inc, Univ Vanderbilt
- What technology area does this patent fall under?
- Primary CPC classification A61K31/336. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).